Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.280
0.00 (0.00%)
At close: Jan 17, 2025, 4:00 PM
1.270
-0.010 (-0.78%)
After-hours: Jan 17, 2025, 6:28 PM EST
Repare Therapeutics Employees
Repare Therapeutics had 179 employees as of December 31, 2023. The number of employees decreased by 1 or -0.56% compared to the previous year.
Employees
179
Change (1Y)
-1
Growth (1Y)
-0.56%
Revenue / Employee
$371,642
Profits / Employee
-$469,542
Market Cap
54.41M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 179 | -1 | -0.56% |
Dec 31, 2022 | 180 | 28 | 18.42% |
Dec 31, 2021 | 152 | 50 | 49.02% |
Dec 31, 2020 | 102 | 38 | 59.38% |
Dec 31, 2019 | 64 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RPTX News
- 11 days ago - Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions - Business Wire
- 5 weeks ago - Why Is Repare Therapeutics Stock Trading Lower On Friday? - Benzinga
- 5 weeks ago - Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
- 5 weeks ago - Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - Business Wire
- 2 months ago - Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - Business Wire
- 2 months ago - Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 3 months ago - Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - Business Wire
- 3 months ago - Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - Business Wire